Half-year report · HY

Period2026-01-01 → 2026-06-30
Filed2026-08-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥1.22T2026-01-01 → 2026-06-30Cons.Revenue IFRS
Revenue¥2.43T2025-01-01 → 2025-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥1.14T2025-01-01 → 2025-06-30Cons.Revenue IFRS
Operating income¥129.0bn2026-01-01 → 2026-06-30Cons.Operating profit loss IFRS
Operating income¥68.7bn2025-01-01 → 2025-06-30Cons.Operating profit loss IFRS
Profit before tax¥150.9bn2026-01-01 → 2026-06-30Cons.Profit loss before tax IFRS
Profit before tax¥237.9bn2025-01-01 → 2025-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥83.8bn2025-01-01 → 2025-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥101.7bn2026-01-01 → 2026-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥147.5bn2025-01-01 → 2025-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥52.8bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥116.1bn2026-01-01 → 2026-06-30Cons.Profit loss IFRS
Net income¥60.5bn2025-01-01 → 2025-06-30Cons.Profit loss IFRS
Total assets¥3.40Tat 2026-06-30Cons.Assets IFRS
Total assets¥3.49Tat 2025-12-31Cons.Assets IFRS
Total assets¥3.30Tat 2025-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥1.72Tat 2026-06-30Cons.Liabilities IFRS
Total liabilities¥1.90Tat 2025-12-31Cons.Liabilities IFRS
Net assets / equity¥1.68Tat 2026-06-30Cons.Equity IFRS
Net assets / equity¥1.60Tat 2025-12-31Cons.Equity IFRS
Net assets / equity¥1.41Tat 2025-06-30Cons.Equity IFRS
Net assets / equity¥1.53Tat 2024-12-31vCons.Equity IFRS
Equity (owners)¥1.36Tat 2026-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.29Tat 2025-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.12Tat 2025-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥168.1bnat 2026-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥125.3bnat 2025-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥132.4bnat 2025-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.6bnat 2024-12-31vCons.Cash and cash equivalents IFRS
Operating cash flow¥137.3bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥295.4bn2025-01-01 → 2025-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥67.3bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥53.7bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥185.0bn2025-01-01 → 2025-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥61.6bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥162.5bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥110.5bn2025-01-01 → 2025-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥35.8bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥126.332026-01-01 → 2026-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥182.132025-01-01 → 2025-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥65.232025-01-01 → 2025-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥182.132025-01-01 → 2025-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥65.222025-01-01 → 2025-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio40.0%at 2026-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio36.8%at 2025-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio34.0%at 2025-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2026-01-01 → 2026-06-30¥46.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2026-01-01 → 2026-06-30¥12.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2026-01-01 → 2026-06-30¥33.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2026-01-01 → 2026-06-30−¥1.5bn
Reconciling Itemsreconcilingrevenue2026-01-01 → 2026-06-30−¥38.9bn
Reconciling Itemsreconcilingrevenue intersegment2026-01-01 → 2026-06-30−¥38.9bn
Reconciling Itemsreconcilingsegment profit2026-01-01 → 2026-06-30−¥34.2bn
Alcoholic Beveragesreportable segmentrevenue2026-01-01 → 2026-06-30¥519.1bn
Alcoholic Beveragesreportable segmentrevenue external2026-01-01 → 2026-06-30¥517.8bn
Alcoholic Beveragesreportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥1.3bn
Alcoholic Beveragesreportable segmentsegment profit2026-01-01 → 2026-06-30¥62.1bn
Health Sciencereportable segmentrevenue2026-01-01 → 2026-06-30¥131.1bn
Health Sciencereportable segmentrevenue external2026-01-01 → 2026-06-30¥128.8bn
Health Sciencereportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥2.3bn
Health Sciencereportable segmentsegment profit2026-01-01 → 2026-06-30¥10.4bn
Non Alcoholic Beveragesreportable segmentrevenue2026-01-01 → 2026-06-30¥296.7bn
Non Alcoholic Beveragesreportable segmentrevenue external2026-01-01 → 2026-06-30¥294.9bn
Non Alcoholic Beveragesreportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥1.8bn
Non Alcoholic Beveragesreportable segmentsegment profit2026-01-01 → 2026-06-30¥31.0bn
Pharmaceuticalsreportable segmentrevenue2026-01-01 → 2026-06-30¥263.6bn
Pharmaceuticalsreportable segmentrevenue external2026-01-01 → 2026-06-30¥263.5bn
Pharmaceuticalsreportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥139m
Pharmaceuticalsreportable segmentsegment profit2026-01-01 → 2026-06-30¥60.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2025-01-01 → 2025-06-30¥47.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2025-01-01 → 2025-06-30¥14.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2025-01-01 → 2025-06-30¥32.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2025-01-01 → 2025-06-30−¥591m
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-06-30−¥38.3bn
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-06-30−¥38.3bn
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-06-30−¥30.0bn
Alcoholic Beveragesreportable segmentrevenue2025-01-01 → 2025-06-30¥493.8bn
Alcoholic Beveragesreportable segmentrevenue external2025-01-01 → 2025-06-30¥492.6bn
Alcoholic Beveragesreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥1.2bn
Alcoholic Beveragesreportable segmentsegment profit2025-01-01 → 2025-06-30¥53.2bn
Health Sciencereportable segmentrevenue2025-01-01 → 2025-06-30¥129.7bn
Health Sciencereportable segmentrevenue external2025-01-01 → 2025-06-30¥127.2bn
Health Sciencereportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥2.5bn
Health Sciencereportable segmentsegment profit2025-01-01 → 2025-06-30¥8.6bn
Non Alcoholic Beveragesreportable segmentrevenue2025-01-01 → 2025-06-30¥273.4bn
Non Alcoholic Beveragesreportable segmentrevenue external2025-01-01 → 2025-06-30¥271.8bn
Non Alcoholic Beveragesreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥1.6bn
Non Alcoholic Beveragesreportable segmentsegment profit2025-01-01 → 2025-06-30¥29.5bn
Pharmaceuticalsreportable segmentrevenue2025-01-01 → 2025-06-30¥230.7bn
Pharmaceuticalsreportable segmentrevenue external2025-01-01 → 2025-06-30¥230.5bn
Pharmaceuticalsreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥156m
Pharmaceuticalsreportable segmentsegment profit2025-01-01 → 2025-06-30¥33.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 869
ItemContextValueUnit
Net increase decrease in short term borrowings fin cf IFRSInterimDuration997000000JPY
Increase decrease in commercial paper fin cf IFRSPrior1InterimDuration107976000000JPY
Increase decrease in commercial paper fin cf IFRSInterimDuration-15995000000JPY
Repayments of long term borrowings fin cf IFRSPrior1InterimDuration-20000000000JPY
Repayments of long term borrowings fin cf IFRSInterimDuration-25000000000JPY
Proceeds from issuance of bonds fin cf IFRSPrior1InterimDuration100000000000JPY
Proceeds from issuance of bonds fin cf IFRSInterimDuration-JPY
Redemption of bonds fin cf IFRSPrior1InterimDuration-25000000000JPY
Redemption of bonds fin cf IFRSInterimDuration-40000000000JPY
Repayments of lease obligations fin cf IFRSPrior1InterimDuration-9506000000JPY
Repayments of lease obligations fin cf IFRSInterimDuration-10037000000JPY
Payments for purchase of treasury shares fin cf IFRSPrior1InterimDuration-9000000JPY
Payments for purchase of treasury shares fin cf IFRSInterimDuration-34554000000JPY
Purchase of treasury stock of subsidiaries in consolidation fin cf IFRSPrior1InterimDuration-4000000JPY
Purchase of treasury stock of subsidiaries in consolidation fin cf IFRSInterimDuration-6000000JPY
Dividends paid fin cf IFRSPrior1InterimDuration-28755000000JPY
Dividends paid fin cf IFRSInterimDuration-29975000000JPY
Dividends paid to non controlling interests fin cf IFRSPrior1InterimDuration-6988000000JPY
Dividends paid to non controlling interests fin cf IFRSInterimDuration-7846000000JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSPrior1InterimDuration-81605000000JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSInterimDuration-JPY
Other fin cf IFRSPrior1InterimDuration-385000000JPY
Other fin cf IFRSInterimDuration-57000000JPY
Net cash provided by used in financing activities IFRSPrior1InterimDuration35825000000JPY
Net cash provided by used in financing activities IFRSInterimDuration-162473000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1InterimDuration-3926000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSInterimDuration14244000000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1InterimDuration37596000000JPY
Net increase decrease in cash and cash equivalents IFRSInterimDuration42783000000JPY
Cash and cash equivalents IFRSPrior2YearInstant118617000000JPY
Cash and cash equivalents IFRSPrior1YearInstant125292000000JPY
Effect of changes in accounting policies cce IFRSPrior2YearInstant-10731000000JPY
Effect of changes in accounting policies cce IFRSPrior1YearInstant-JPY
Restated cash and cash equivalents at beginning of period cce IFRSPrior2YearInstant107886000000JPY
Restated cash and cash equivalents at beginning of period cce IFRSPrior1YearInstant125292000000JPY
Net increase decrease in cash and cash equivalents resulting from transfer to assets held for sale IFRSPrior1InterimDuration-13074000000JPY
Net increase decrease in cash and cash equivalents resulting from transfer to assets held for sale IFRSInterimDuration-JPY
Cash and cash equivalents IFRSPrior1InterimInstant132408000000JPY
Cash and cash equivalents IFRSInterimInstant168075000000JPY
Revenue from external customers IFRSPrior1InterimDuration_jpcrp040300-ssr_E00395-000AlcoholicBeveragesReportableSegmentMember492628000000JPY
Revenue from external customers IFRSPrior1InterimDuration_jpcrp040300-ssr_E00395-000NonAlcoholicBeveragesReportableSegmentMember271805000000JPY
Revenue from external customers IFRSPrior1InterimDuration_jpcrp040300-ssr_E00395-000PharmaceuticalsReportableSegmentMember230498000000JPY
Revenue from external customers IFRSPrior1InterimDuration_jpcrp040300-ssr_E00395-000HealthScienceReportableSegmentMember127247000000JPY
Revenue from external customers IFRSPrior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember14132000000JPY
Revenue from external customers IFRSPrior1InterimDuration_ReconcilingItemsMember-JPY
Revenue from external customers IFRSPrior1InterimDuration1136309000000JPY
Intersegment revenue IFRSPrior1InterimDuration_jpcrp040300-ssr_E00395-000AlcoholicBeveragesReportableSegmentMember1159000000JPY
Intersegment revenue IFRSPrior1InterimDuration_jpcrp040300-ssr_E00395-000NonAlcoholicBeveragesReportableSegmentMember1598000000JPY
Intersegment revenue IFRSPrior1InterimDuration_jpcrp040300-ssr_E00395-000PharmaceuticalsReportableSegmentMember156000000JPY
Intersegment revenue IFRSPrior1InterimDuration_jpcrp040300-ssr_E00395-000HealthScienceReportableSegmentMember2489000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2025-12-31pass rounding
balance sheet identityconsolidated 2026-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · net income attributable to parentconsolidated 2026-01-01/2026-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2026-01-01/2026-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2026-01-01/2026-06-30pass
statement vs summary · total assetsconsolidated 2025-12-31pass
statement vs summary · total assetsconsolidated 2026-06-30pass